Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist (177)Lu‐DOTAGA‐PEG(2)‐RM26

Gastrin‐releasing peptide receptors (GRPRs) are overexpressed in prostate cancer and are suitable for targeted radionuclide therapy (TRT). We optimized the bombesin‐derived GRPR‐antagonist PEG(2)‐RM26 for labeling with (177)Lu and further determined the effect of treatment with (177)Lu‐labeled pepti...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Int J Cancer
Huvudupphovsmän: Mitran, Bogdan, Rinne, Sara S., Konijnenberg, Mark W., Maina, Theodosia, Nock, Berthold A., Altai, Mohamed, Vorobyeva, Anzhelika, Larhed, Mats, Tolmachev, Vladimir, de Jong, Marion, Rosenström, Ulrika, Orlova, Anna
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley & Sons, Inc. 2019
Ämnen:
Cancer Therapy and Prevention
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6852655/
https://ncbi.nlm.nih.gov/pubmed/31077356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32401
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk